These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 17116941)

  • 61. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
    Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
    Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
    Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
    J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjuvant docetaxel for high-risk, node-negative breast cancer.
    Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
    N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
    Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
    Abe H; Mori T; Kawai Y; Cho H; Kubota Y; Umeda T; Kurumi Y; Tani T
    Int J Clin Oncol; 2013 Jun; 18(3):487-91. PubMed ID: 22484576
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
    Espinosa E; Morales S; Borrega P; Casas A; Madroñal C; Machengs I; Illarramendi JA; Lizón J; Moreno JA; Belón J; Janáriz J; de la Puente M; Checa T; Mel JR; González Barón M
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):546-52. PubMed ID: 15316749
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
    Gérard JP; Héry M; Gedouin D; Monnier A; Goudier MJ; Jacquin JP; Plat F; Cabarrot E; Serin D; Namer M
    Drugs; 1993; 45 Suppl 2():60-7. PubMed ID: 7693424
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
    Assi H; Murray J; Boyle L; Rayson D
    Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
    Fumoleau P; Devaux Y; Vo Van ML; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
    Drugs; 1993; 45 Suppl 2():38-45. PubMed ID: 7693420
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.